Company: HCWB
Filing Date: 2025-08-19
Form Type: 8-K
Source: 0000950170-25-110174
Chunk: 1

Company: HCW Biologics Inc.
Filing Date: 2025-08-19
Form: 8-K
Item: Item 3.01
Chunk 1
---
 Company’s intent to request a hearing before the Panel Monitor and the Company’s expectations regarding how long it may remain listed on The Nasdaq Capital Market. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, including the risk that the Company may not be successful in its appeal to the Panel Monitor, the risk that the Company may not otherwise meet the requirements for continued listing under the Nasdaq Listing Rules, the risk that Nasdaq may not grant the Company relief from delisting if necessary, and the risk that the Company may not ultimately meet applicable Nasdaq requirements for any such relief, among other risks and uncertainties.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                           HCW BIOLOGICS INC.                                 
  Date:      August 19, 2025      By:      /s/ Hing C. Wong                                   
                                           Hing C. Wong, Founder and Chief Executive Officer